Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIPEC + systemic conversion therapy and CRS for colorectal and appendiceal cancer with peritoneal metastasis
ChiCTR2600124441Phase 2Recruiting
- Sponsor
- Jinling Hospital
- Start
- May 2026
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of raltitrexed, bevacizumab, sintilimab, tremelimumab, durvalumab and 4 more in colorectal cancer (CRC), appendiceal mucinous neoplasm (MAN) and peritoneal carcinomatosis (PC), sponsored by Jinling Hospital. Primary endpoint: Conversion surgery rate. Started May 2026; status: recruiting.
02
Drugs
raltitrexedbevacizumabsintilimabtremelimumabdurvalumab
03
Conditions
colorectal cancer (CRC)appendiceal mucinous neoplasm (MAN)peritoneal carcinomatosis (PC)
Beyond the preview
Go deeper on ChiCTR2600124441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124441.